Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.55 USD | -1.39% | +13.42% | +184.00% |
05-08 | Lexaria Bioscience Corp. Begins Dosing of Its Second Glp-1 Human Pilot Study | CI |
04-16 | Lexaria Obtains Ethics Review Board Approval to Start New GLP-1 Study | MT |
Sales 2024 * | 596K 47.6M | Sales 2025 * | 488K 38.93M | Capitalization | 45.74M 3.65B |
---|---|---|---|---|---|
Net income 2024 * | -5M -399M | Net income 2025 * | -7M -559M | EV / Sales 2024 * | 76.8 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 93.8 x |
P/E ratio 2024 * |
-7.72
x | P/E ratio 2025 * |
-7.98
x | Employees | 5 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 87.23% |
1 day | -1.39% | ||
1 week | +13.42% | ||
Current month | +14.89% | ||
1 month | +41.43% | ||
3 months | +54.35% | ||
6 months | +151.77% | ||
Current year | +184.00% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 62 | 25/10/06 | |
John Docherty
PSD | President | 53 | 14/04/15 |
George Jurcic
IRC | Investor Relations Contact | - | 30/04/21 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 62 | 25/10/06 | |
Nicholas Baxter
BRD | Director/Board Member | 70 | 07/07/11 |
Albert Reese
BRD | Director/Board Member | 74 | 13/01/21 |
Date | Price | Change | Volume |
---|---|---|---|
10/05/24 | 3.55 | -1.39% | 256,011 |
09/05/24 | 3.6 | +1.69% | 192,366 |
08/05/24 | 3.54 | +3.21% | 106,814 |
07/05/24 | 3.43 | +0.59% | 226,517 |
06/05/24 | 3.41 | +8.95% | 294,182 |
Delayed Quote Nasdaq, May 10, 2024 at 09:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+184.00% | 45.74M | |
+30.38% | 684B | |
+26.51% | 568B | |
-4.36% | 361B | |
+19.30% | 329B | |
+3.73% | 284B | |
+16.70% | 240B | |
+8.78% | 208B | |
-7.93% | 200B | |
+7.68% | 166B |
- Stock Market
- Equities
- LEXX Stock